Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield Street, Detroit, MI 48201, USA.
Department of Pathology, Oslo University Hospital, N-0310 Oslo, Norway.
Int J Mol Sci. 2024 Mar 8;25(6):3119. doi: 10.3390/ijms25063119.
Photodynamic therapy (PDT) has been a topic of interest since the first report in 1900 but has yet to become a 'mainstream' treatment protocol in the medical field. There are clear indications for which PDT might be the 'method of choice', but it is unlikely that there will be protocols for the treatment of systemic disease. This report discusses recent developments for promoting PDT efficacy, in the context of what is already known. Factors that can limit the scope of these applications are also indicated. Among the more interesting of these developments is the use of formulation techniques to target specific organelles for photodamage. This can enhance responses to PDT and circumvent situations where an impaired death pathway interferes with PDT efficacy.
光动力疗法（PDT）自 1900 年首次报道以来一直是研究热点，但尚未成为医学领域的“主流”治疗方案。有明确的适应症表明 PDT 可能是“首选方法”，但不太可能有针对系统性疾病的治疗方案。本报告讨论了在现有知识背景下提高 PDT 疗效的最新进展。还指出了可能限制这些应用范围的因素。在这些进展中，比较有趣的是使用制剂技术将特定细胞器作为光损伤的靶点。这可以增强对 PDT 的反应，并规避受损的死亡途径干扰 PDT 疗效的情况。
Zotero 插件